Taysha Gene Therapies, Inc. (TSHA) Free cash flow 2020–2025
Taysha Gene Therapies, Inc. (TSHA) annual free cash flow history — operating cash flow minus capital expenditures, per SEC filings.
-$93.8MFY2025 · since FY2020: -$30.8M → -$93.8M
| Fiscal year | Value | YoY |
|---|---|---|
| FY2025 | -$93.8M | -15.0% |
| FY2024 | -$81.6M | -6.1% |
| FY2023 | -$76.9M | +29.5% |
| FY2022 | -$109.0M | +17.6% |
| FY2021 | -$132.3M | -329.5% |
| FY2020 | -$30.8M | — |
Free cash flow = reported operating cash flow − reported capital expenditures for the same fiscal year.
Source: SEC XBRL filings · For reference only · Not investment advice
More TSHA financial trends
TSHA RevenueTSHA Net incomeTSHA Net marginTSHA Gross profitTSHA Gross marginTSHA Operating incomeTSHA Operating marginTSHA Operating cash flowTSHA Capital expendituresTSHA Return on equityTSHA Stock buybacksTSHA Dividends paidTSHA Total assetsTSHA Total liabilitiesTSHA Shareholders’ equityTSHA overview →